Central Nervous System: Strategic Biosimulation Services

Certara has supported over 65 Central Nervous System (CNS) projects for industry clients over the past five years, spanning all phases of clinical development. Our consultants have addressed key issues in trial design, choice of indication, and development strategy for drugs with novel mechanisms of action. We have developed models for assessing the probability a drug in development will be competitive with the standard of care.

Our experience covers a broad range of diseases and conditions within the CNS. Our compilations of public data from the clinical and scientific literature in several CNS disease areas provide a ready context for model-based meta-analysis to assess your compound's performance against competing therapies.

Number and types of projects

  • 67 projects over the last 8 years
  • Type - protein, small molecule, peptide
  • Mechanisms of action - GABAA receptor modulators, VMAT-2 inhibitors, type II glucocorticoid, cortisol, and progesterone receptors, dopaminergic modulators, serotonergic modulators, gamma secretase inhibitors, noradrenergic modulators, cannabinoid-2 receptor agonist, histamine H3 receptor antagonist and inverse agonist, BACE-1 inhibitors, TRPV1 receptors
  • Disease areas
    • Acute trauma
    • Attention deficit hyperactivity disorder (ADHD)
    • Alzheimer's disease
    • Amytrophic lateral sclerosis (ALS)
    • Anxiety disorders/Panic attacks
    • Bipolar disorder
    • Chorea associated with Huntington’s disease
    • Cocaine addiction
    • Depression
    • Epilepsy
    • Excessive daytime sleepiness (EDS)
    • Insomnia
    • Major depressive disorder
    • Multiple sclerosis
    • Narcolepsy
    • Neuropathic pain
    • Postherpetic neuralgia (PHN)
    • Psychotic major depression (PMD)

We can help you to develop a modeling and simulation strategy for establishing a comprehensive picture of your CNS drug’s safety and efficacy profile to accelerate clinical development.